Dr. Richard M. Stone on the Genetic Landscape in AML

Richard M. Stone, MD
Published: Thursday, Oct 06, 2016


Richard M. Stone, MD, chief of staff, program director, adult leukemia, institute physician, professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses what is currently understood regarding the genetic landscape in acute myeloid leukemia (AML).
 
The number of mutations in any given patient’s blasts are probably lower in total in AML than they are in solid tumor patients, says Stone. The types of mutations can be subdivided into different categories, which may lead it self to the development of specific therapeutics.
 
Assessing mutations at the time of diagnosis also offers additional prognostic information, which is some cases can be used to decide on therapy.
 
SELECTED
LANGUAGE

Richard M. Stone, MD, chief of staff, program director, adult leukemia, institute physician, professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses what is currently understood regarding the genetic landscape in acute myeloid leukemia (AML).
 
The number of mutations in any given patient’s blasts are probably lower in total in AML than they are in solid tumor patients, says Stone. The types of mutations can be subdivided into different categories, which may lead it self to the development of specific therapeutics.
 
Assessing mutations at the time of diagnosis also offers additional prognostic information, which is some cases can be used to decide on therapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x